Line Oste
Galapagos (Belgium)(BE)
Publications by Year
Research Areas
Bone health and treatments, Parathyroid Disorders and Treatments, Bone health and osteoporosis research, Peptidase Inhibition and Analysis, Asthma and respiratory diseases
Most-Cited Works
- → Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis(2017)137 cited
- → Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic(2014)109 cited
- → Effects of Strontium on the Physicochemical Characteristics of Hydroxyapatite(2004)106 cited
- → Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate(2005)88 cited
- → A multiparameter approach to monitor disease activity in collagen-induced arthritis(2010)82 cited
- → Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats(2005)55 cited
- → Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial(2020)43 cited
- → IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases(2023)39 cited
- → Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis(2021)30 cited
- → Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats(2006)21 cited